No Data
No Data
TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $60
TD Cowen Remains a Buy on Vera Therapeutics (VERA)
LifeSci Capital Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $70
Buy Rating Affirmed for Vera Therapeutics Amid Promising Atacicept Prospects and Market Overreaction Concerns
Vera Plunges as Otsuka Updates on Rival Therapy
Wells Fargo Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $70